Abstract
BackgroundTo evaluate the value of serum Lactate Dehydrogenase (LDH) level in predicting recurrence and the overall survival (OS) of glioma patients. Materials and methodsA total number of 216 patients with glioma in our institution were retrospectively recruited to analyze the relationship between preoperative serum LDH level and prognosis. ResultsOverall, the median age of patients was 46.0 (31.0–57.0) years old; 53.7% (116 of 216) of the enrolled patients were male. Multivariate analysis revealed that serum LDH level (odds ratio [OR] = 0.97, 95% confidence interval [CI] = 0.96–0.98, P < 0.001) and World Health Organization (WHO) grade (grade II: OR = 19.64, 95%CI = 5.56–69.35, P < 0.001; grade III: OR =1 9.50, 95%CI = 7.08–53.73, P < 0.001; grade IV: OR = 15.23, 95%CI = 4.94–46.97, P < 0.001) were significant and independent of 1-year Progression-free survival (PFS) after adjusting for confounders. The predictive performance of serum LDH level was represented with area under curve (AUC) = 0.741, 95%CI = 0.677–0.798. Multivariate Cox analysis revealed that LDH level (hazard ratio [HR] = 2.56, 95%CI = 1.59–4.15, P < 0.001) and WHO grade (grade II: HR = 4.58, 95%CI = 0.56–37.23, P = 0.155; grade III: HR = 16.35, 95%CI = 2.16–123.80, P = 0.007; grade IV: HR = 42.13, 95%CI = 5.83–304.47, P < 0.001) remained associated with survival at 2-year follow-up. At 3-year follow-up, lymphocyte count (HR = 0.68, 95%CI = 0.51–0.91, P = 0.008), LDH level (HR = 2.21, 95%CI = 1.40–3.49, P = 0.001), and WHO grade (grade II: HR = 1.44, 95%CI = 0.44–4.68, P = 0.543; grade III: HR = 4.99, 95%CI = 1.68–14.87, P = 0.004; grade IV: HR = 16.96, 95%CI = 6.13–46.93, P < 0.001) remained associated with survival in multivariate Cox analysis. ConclusionOur study demonstrated that preoperative serum LDH level could serve as a reliable indicator for predicting prognosis of glioma patients. Further multicenter studies are still required to verify our findings.
Highlights
Glioma is a common type of intracranial malignant tumor, accounting for 15.1% of central nervous system tumor
Multivariate analysis revealed that serum Lactate Dehydrogenase (LDH) level and World Health Organization (WHO) grade were significant and independent of 1-year Progression-free survival (PFS) after adjusting for confounders
The predictive performance of serum LDH level was represented with area under curve (AUC) = 0.741, 95%CI=0.677-0.798
Summary
Glioma is a common type of intracranial malignant tumor, accounting for 15.1% of central nervous system tumor. There are approximately 30 thousand people die from glioma worldwide every year 1. The clinical behaviors of glioma are highly variable and complex, including hemiplegia, epilepsy, and vomiting. The maximum safe surgical resection combining with radiation therapy and chemotherapy is the current standard therapy which improved the prognosis of those patients. High-grade glioma is characterized by high mortality rates and rapid progression. It is difficult to ensure the quality of life in patients with glioma due to high rate of operative complications. Predicting prognosis in patients with glioma is both a difficult and important task for clinicians. To evaluate the value of serum Lactate Dehydrogenase (LDH) level in predicting recurrence and the overall survival (OS) of glioma patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
